Definium's DT120 meets Phase 3 primary endpoint for major depressive disorder

Definium announced positive topline results from the Emerge Phase 3 study, with DT120 ODT demonstrating an 8.1-point placebo-adjusted improvement on the MADRS scale at Week 6 (p<0.0001) and durable effects through Week 12. The single-dose treatment was well-tolerated with no serious adverse events, potentially supporting FDA submission for a novel psychiatric treatment.